Analysis of more than 900 patients enrolled in real-world registry
demonstrates improved clinical decisions when FFR is used to guide
cardiac treatment procedures
“Data from the POST-IT registry provides further evidence of the benefits associated with FFR measurement technology in a real-world setting,” said
POST-IT is a national, prospective, multi-center registry that enrolled 918 eligible patients at 19 centers in
“Collectively, these findings show that when FFR-guided therapy is used, cardiologists can significantly improve patient management,” said LuÍs F. Raposo, M.D., of Hospital de
“St. Jude Medical welcomes the abundance of positive data that continues to demonstrate the profound role FFR has on improving patient care,” said Dr.
POST-IT Registry Protocol
The POST-IT registry required all patients to first undergo a coronary angiogram. Based on the results of the coronary angiography, the supervising cardiologist was asked to create an initial management plan for each patient, based on all available information. Once the original treatment plan was finalized, patients underwent FFR assessment of all vessels suitable for revascularization (whether PCI or CABG), which were defined as those =2.25 mm. After FFR results were known, the supervising cardiologist was then asked to revise their final treatment decision. Consistency between the final and initial management plans were then evaluated.
FFR is a physiological index used to determine the hemodynamic severity of narrowings (or lesions) in the coronary arteries, and is measured using St. Jude Medical PressureWire™ Aeris. FFR specifically identifies which coronary narrowings are responsible for obstructing the flow of blood to a patient’s heart muscle (called ischemia), and helps guide the interventional cardiologist in determining which lesions warrant stenting, which can result in improved patient outcomes and reduced healthcare costs.
To learn more about FFR-guided therapy or see a demo of the PressureWire™ fractional flow reserve (FFR) measurement technology, EuroPCR attendees can visit
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the
Most Popular Stories
- Shia LaBeouf Plea Deal, Alcoholism Treatment
- Ohio State Band Chief Fired After Probe
- Stop-Start Engines Save Gas, Reduce Emissions
- Hispanic Leader Goes the Extra Mile
- Ukraine Says Russians Firing Across the Border
- Jennifer Lopez, Pitbull to Perform at Fashion Rocks
- Ricky Martin Joins 'The Voice ... Mexico'
- Ford Q2 Net Profit up 6 Percent
- U.S. Weighs Refugee Status for Immigrant Kids
- Morgan Stanley Ponies Up $275 Million to Settle SEC Charges